Document:

Exhibit 10.2

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

execution
copy

 

MASTER
SERVICES AGREEMENT

 

This Master Services
Agreement (this “Agreement”) is entered into as of July 20, 2017 (the “Effective Date”)
by and between ArQule, Inc., a Delaware corporation having a place of business
at One Wall Street, Burlington, MA 01803 (“ArQule”) and ARUP Laboratories
Inc., a Utah nonprofit organization having its principal place of business at 500 Chipeta Way, Salt Lake City,
UT 84108 (“ARUP”). ArQule and ARUP may be referred to herein individually as a “Party” and
collectively as the “Parties.”

 

RECITALS

 

WHEREAS, ARUP and
its Affiliates are engaged in the business of supplying specialized assay and Companion Diagnostic development and testing services;

 

WHEREAS, ArQule is
pursuing a clinical development program of ARQ 087 in subjects with Intrahepatic Cholangiocarcinoma (“iCCA”);

 

WHEREAS, pursuant
to the terms of a Master Collaboration Agreement (the “MCA”) dated as of July 20, 2017 by and between ArQule
and that certain third party manufacturer of the *** set forth in Exhibit 1 hereto (the “Supplier”), ArQule
and the Supplier have agreed to commercialize an in vitro diagnostic and/or companion diagnostic for the
ArQule Compound (as defined below) in certain European and other countries;

 

WHEREAS, ArQule desires
to engage and contract for the services of ARUP for the development, validation, regulatory approval and commercialization of
a Companion Diagnostic assay in the United States (as defined below) that meets FDA requirements for use by ArQule in the above
identified clinical development program and ARUP is willing to provide such services, on the terms set forth herein; and

 

WHEREAS, following
validation and regulatory approval of the Companion Diagnostic test, ARUP will commercialize the test in accordance with the terms
to be included in a Statement of Work to be executed by the Parties.

 

NOW, THEREFORE, In
consideration of the above recitals and mutual covenants contained herein, the Parties agree as follows:

 

1.          Definitions.
As used in this Agreement:

 

1.1           “Applicable
Laws” means all relevant United States federal, state and local laws, statutes, rules, and regulations including any
rules, regulations or requirements of any Regulatory Authority, that are applicable to a Party’s activities hereunder.

 

1.2           “Affiliate”
means, with respect to a Party, a person or business entity that directly or indirectly controls, or is controlled by, or
is under common control with, that Party. For purposes of this definition, the term “control,” including the terms
“controlled by” or “under common control with,” means (a) owning
fifty percent (50%) or more of the voting stock of a company or (b) the
possession of, directly or indirectly, the capability to control the direction of the management and policies through the ownership
of voting securities or control the board of directors or equivalent governing body
of an organization.

 

    	 	Page 1 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

1.3           “ArQule
Background Patents” means any Patents Controlled by ArQule that contain one or more claims that cover ArQule Background
Know-How.

 

1.4           “ArQule
Background Know-How” means any Know-How that (a) is Controlled by
ArQule as of the Effective Date and/or during the Term, (b) Covers the ArQule Compound and/or any ArQule Materials and (c) is
necessary or useful for ARUP to perform the Project. For purposes of clarity, ArQule Background Know-How (i)
shall not include any ArQule Inventions and (ii) shall include, without limitation,
any Know-How that is specifically described as ArQule Background Know-How in
any Scope of Work.

 

1.5           “ArQule
Compound” means the proprietary compound of ArQule designated by ArQule as ARQ 087.

 

1.6           “ArQule
Contact” means ArQule’s contact person for a particular Scope of Work as identified in the Scope of Work.

 

1.7           “ArQule
Invention” means any Invention that (a) relates to the composition, synthesis, formulation, mechanism of action and/or
use of the ArQule Compound and/or (b) is a process or method of manufacture
of the ArQule Compound. For purposes of clarity, ArQule Invention shall
not include the Companion Diagnostic.

 

1.8           “ArQule
Materials” means all Materials provided by ArQule to ARUP for use in the Project. For clarity, all ArQule Materials
will be described in a Scope of Work.

 

1.9           “ARUP
Background Patents” means any Patents Controlled by ARUP that contain one or more claims that Cover ARUP Background
Know-How.

 

1.10         “ARUP
Background Know-How” means any Know-How that is Controlled by ARUP as of the Effective Date and/or during the Term,
and used by ARUP in the conduct of the Project. For purposes of clarity, ARUP Background Know-How (a)
shall not include any ARUP Inventions. and (b) shall include,
without limitation, (i) the PDP and (ii) any Know-How that is specifically described as ARUP Background Know-How in any Scope
of Work. 

 

1.11         “ARUP
Companion Diagnostic” means the Companion Diagnostic incorporating the Supplier ***
developed by ARUP to be used in conjunction and/or commercialized with the ArQule Compound in the Territory.

 

1.12         “ARUP
IUO” means the diagnostic test developed by ARUP incorporating the Supplier ***
for investigational use only in Clinical Trials with the ArQule Compound.

 

1.13         “ARUP
Invention” means any Invention that (a) does not relate to (i) the composition,
synthesis, formulation, mechanism of action, use or manufacture of the ArQule Compound and/or (ii) ArQule Background Know-How,
and (b) relates specifically to ARUP Background Know-How including the PDP).
For purposes of clarity, the Companion Diagnostic will be considered an ARUP Invention and is not considered to be related to
the ArQule Compound and/or ArQule Background Know-How.

 

    	 	Page 2 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

1.14         “ARUP
Invention Patents” means any Patents that contain one or more claims that cover any ARUP Invention.

 

1.15         “Companion
Diagnostic” means a diagnostic test that is intended to be commercialized for use (a) in identifying patients who may
or may not be suitable for treatment with one or more prescription pharmaceutical products, or (b) otherwise in conjunction with
the treatment of patients with a prescription pharmaceutical product, including a diagnostic test that meets the definition of
“IVD companion diagnostic device” as set forth in FDA’s Guidance for Industry and Food and Drug Administration
Staff on In Vitro Companion Diagnostic Devices of August 6, 2014.

 

1.16         “Confidential
Information” any confidential and/or
proprietary data, information and/or Know-How of a Party that is provided by
such Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) in connection
with this Agreement, whether communicated in writing, electronically or orally, including any such information relating
to any Assay, diagnostic, biomarker, genetic sequence, compound, Materials, research project,
clinical and preclinical data, work in process, future development, scientific, engineering, launch, manufacturing, marketing,
business plan, financial or personnel matter relating to such Disclosing Party,
its present or future products, sales, suppliers, customers, employees, investors and business, whether or not marked or described
in writing as “confidential”, “proprietary” or the like. For
purposes of clarity, (a) all ArQule Inventions and ArQule Project Results shall be Confidential Information of ArQule, and (b)
all ARUP Inventions, the PDP and ARUP Project Results shall be Confidential Information of ARUP. The terms and conditions
of this Agreement and any Scope of Work shall be Confidential Information of ArQule
and ARUP.

 

1.17         “Commercially
Reasonable Efforts” means, with respect to an objective, the reasonable, diligent, good faith efforts of a Party of
the type to accomplish such objective that a company in
the industry of a similar size and profile as such Party would normally use to accomplish a similar
objective taking into account all applicable scientific, commercial and other
relevant factors.

 

1.18         “Control”
or “Controlled by” means, with respect to any item of
information, material, Patents or other intellectual property assets, that a Party owns or that a Party otherwise has the right
to grant a license, sublicense or other right (including a right of reference) to such assets without violating the terms of any
written agreement with any third party.

 

1.19         “
Covers” or Covered by” means, with respect to a particular item
or form of Intellectual Property, that such Intellectual Property cannot be practiced, used, made, or sold without infringing
upon or misappropriating certain other Intellectual Property rights.

 

1.20         “Deliverables”
means the items specifically designated or characterized as deliverables in a Scope of Work.

 

    	 	Page 3 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

1.21         “Drug
Development Failure” means, with respect to the ArQule Compound, that
ArQule has provided ARUP with written notice that it has discontinued development
of such ArQule Compound for any indication.

 

1.22         “FDA”
means the United States Food and Drug Administration or any successor entity thereto.

 

1.23         “Intellectual
Property” or “IP” means all intellectual property, including Patents, Know-How, discoveries, inventions,
developments, trade secrets, techniques, methodologies, modifications, innovations, improvements, writings, documentation, electronic
code, data and rights (whether or not protectable under state, federal or foreign patent, trademark, copyright or similar laws)
or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether
or not patentable or copyrightable; provided, that, “Intellectual Property” shall not, unless clearly indicated to
the contrary, include names, logos, trademarks, trade dress and service marks.

 

1.24         “Invention”
means any Know-How (including, without limitation, any new and useful process, method of manufacture or composition of matter)
that is conceived or first reduced to practice by ARUP, any Affiliate of ARUP and/or any Approved Subcontractor in the conduct
of the Services.

 

1.25         “Joint
Invention” means any Invention that is not an ArQule Invention nor
an ARUP Invention.

 

1.26         “Know-How”
means any information, improvements, practices, formula, trade secrets, techniques, procedures, knowledge, skill, experience
and results, including any
information regarding marketing, pricing, distribution, cost, sales or manufacturing.

 

1.27         “Materials”
means those materials supplied by either Party for use in connection with the Services.

 

1.28         
“Patent” means any existing or future: (a) national, regional or international patent or patent application
in any jurisdiction (including any provisional, divisional, continuation, continuation-in-part, non-provisional, converted provisional,
or continued prosecution application, any utility model, petty patent, design patent and/or certificate of invention), (b)
any extension, restoration, revalidation, reissue, re-examination and extension (including any supplementary protection
certificate and the like) of any of the foregoing patents or patent applications, and (c)
any ex-U.S. equivalents corresponding to any of the foregoing.

 

1.29         “Product
Development Program” or “PDP” means ARUP’s proprietary design control program, consisting of
standard operating procedures utilized during general assay (including CDx) development, validation and commercialization. For
clarity, the PDP (a) is the sole property of ARUP, and (b) is not a component
of the Deliverables or the Results.

 

1.30         “Project”
means the full range of services to be provided by ARUP under this Agreement as more fully described in a Scope of Work.

 

    	 	Page 4 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

1.31         “Regulatory
Authority” means any United States regulatory authority, including the FDA, with authority over conduct of the Services
and/or the use of any Deliverables.

 

1.32         “Results”
means all data and results produced or developed by ARUP in the conduct of the Services, including all Reports.

 

1.33         “Services”
means the services specifically set forth in a Scope of Work.

 

1.34         “Specifications”
means any procedures, process parameters, analytical tests and other attributes and written specifications for the Services
and Deliverables included in a Scope of Work.

 

1.35         “Supplier
***” means ***.

 

2.          Services

 

2.1           Scope.
The details of the Services to be performed by ARUP under this Agreement shall be specified in writing on terms and in a form
acceptable to the Parties (each, a “Scope of Work”), and subject to the terms and conditions set forth in this
Agreement. . An initial form of Scope of Work is attached hereto as Exhibit A. Each Scope of Work shall
include, as appropriate, the scope of the work to be performed, time line, budget, other Deliverables, as well as a payment schedule.
Each Scope of Work shall be subject to all of the terms and conditions of this Agreement, in addition to the specific details
set forth in any Scope of Work. A Scope of Work may be entered into by ArQule or, as applicable, an ArQule Affiliate. Affiliates
of ArQule may become a Party to this Agreement by such Affiliate executing a
Scope of Work. Any such Affiliate of ArQule will be bound to the terms and conditions
under this Agreement and shall have the rights and obligations applicable to ArQule under this Agreement for the respective Scope
of Work. Should any provision in any exhibits or attachments hereto conflict with any of the provisions in this Agreement, this
Agreement shall control unless such conflicting provision specifically states otherwise.

 

2.2           Performance
of Services. ARUP shall use Commercially Reasonable Efforts, and be diligent,
in the performance of Services and in meeting its obligations hereunder. The Services shall be performed by ARUP in a professional,
workmanlike manner, consistent with industry standards, and in accordance with Applicable Laws. ARUP shall furnish all tools,
equipment, supplies or other overhead items necessary to perform the Services required under this Agreement, unless, and only
to the extent that, the applicable Scope of Work specifies otherwise, or to the extent that any Scope of Work contemplates the
transfer of certain Materials or ArQule Intellectual Property as a necessary component of ARUP performing the Services. ARUP makes
no representations regarding the outcome of the Project, and specifically disclaims any particular result with respect to FDA
approval of the diagnostic method developed by ARUP, as a “Companion Diagnostic,” under the
FDA regulations, or that such method will be eligible for classification as a “Humanitarian Use Device,” eligible
for a “Humanitarian Device Exemption,” or that any other outcome of the
Project will be achieved with respect to the FDA or any other Regulatory
Authority.

 

    	 	Page 5 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

2.3           Change
Orders. Any material change in the details of a Scope of Work or the assumptions upon which any Scope of Work is based may
require changes in the scope, budget and/or timelines of Services, and shall require a written amendment to any Scope of Work
(a “Change Order”). If at any time during the Term, either Party reasonably determines that a Change Order
is necessary, such Party shall prepare a Change Order describing in reasonable detail the nature of such additional Services,
and submit such Change Order to the other Party for its review and written approval. Each such Change Order shall detail the requested
changes to the applicable task, responsibility, duty, budget, timeline or other matter. The Change Order shall become effective
upon the execution of the Change Order by both Parties. Both Parties agree to act in good faith and promptly when considering
a Change Order requested by the other Party. Change Orders shall be attached to this Agreement and incorporated herein. A Change
Order may, but need not, include an increase in fees payable under any Scope of Work.

 

2.4           Project
Management.

 

2.4.1           Project
Manager. ARUP shall appoint one of its employees as the “Project Manager” for each Scope of Work. The Project
Manager shall be responsible for all aspects of the Services under such Scope of Work through completion of such Services. Such
Project Manager shall regularly report progress on such Scope of Work to the ArQule Contact for such Scope of Work, and coordinate
with such ArQule Contact for the performance of the Services. Unless otherwise agreed, all communications between ArQule and ARUP
regarding the conduct of the Services pursuant to a Scope of Work shall be addressed between such Project Manager and ArQule Contact.
The Project Manager shall respond to any communication from ArQule with reasonable promptness after his/her receipt of such communication.

 

2.4.2           Joint
Steering Committee. The Parties hereby establish a Joint Steering Committee (the “JSC”), which will be
comprised of an equal number (not less than three (3)) of representatives of each of the Parties. The JSC will meet on dates mutually
agreed to by the Parties not less than once per Calendar Quarter, in person or by teleconference which, if in person, shall alternate
between the offices of the Parties. ArQule will be responsible for the costs and expenses incurred by (i)
its representative in participating on the JSC and (ii) ARUP’s representative
in participating on the JSC, as set forth in in the Scope of Work. The JSC shall be responsible for (a) overseeing the
conduct and progress of the Project; (b) ensuring the exchange of Reports and Results by the Parties; and (c) attempting to resolve
any dispute that may arise between the Parties with respect to this Agreement. Except as otherwise agreed to by the Parties, the
JSC shall have no authority to make any decisions binding on either of the Parties with respect to either Party’s performance
under this Agreement.

 

2.5           Timelines.
The Parties shall use commercially reasonable efforts to comply with any timelines, milestones, schedules or target dates for
completing the Services or any portion thereof as set forth in such Scope of Work. If at any time a Party anticipates a delay
in meeting such timelines for a given Scope of Work, said Party shall promptly notify the other Party in writing of such anticipated
delay and the estimated duration of such delay.

 

    	 	Page 6 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

2.6           Materials.
To the extent specified in a particular Scope of Work, ArQule shall promptly provide ARUP with sufficient amounts of the ArQule
Materials for ARUP to perform the Services; provided, that, ARUP hereby acknowledges that the
Supplier *** related to the Companion Diagnostic developed by ARUP under this Agreement will be provided by the Supplier
pursuant to a separate supply agreement to be executed by and among ARUP,
the Supplier and ArQule (the “*** Supply Agreement”).
ArQule acknowledges and agrees that ARUP’s obligations under this Agreement are contingent upon the execution by ARUP of
the *** Supply Agreement and compliance by the Supplier of its obligations to provide
such Materials to ARUP in accordance with the terms of the *** Supply Agreement. Except as otherwise set forth in a Scope
of Work, ARUP shall use the ArQule Materials provided by ArQule solely to perform the Services under such Scope of Work and for
no other purpose, and in compliance with ArQule’s instructions and Applicable Laws. ARUP shall not sell, transfer, disclose
or otherwise provide access to the ArQule Materials provided by ArQule to any person or entity without the prior written consent
of ArQule. Upon written request following completion or termination of the applicable Services, ARUP shall return or destroy the
ArQule Materials provided by ArQule and, if destroyed, certify such destruction in writing, upon completion or termination of
the applicable Services.

 

2.7           Records.
ARUP will maintain records of all Results obtained or generated by ARUP in the course of providing Services, including all
computerized records and files, in accordance with Applicable Laws and industry standards in a secure area. Upon the written request
of ArQule, copies of all such records will be delivered to ArQule or to its designee in such form as is then currently in the
possession of ARUP. In the event any requested records contain Confidential Information of ARUP,
ARUP Background Know-How, or ARUP Background Patents (collectively, “ARUP Proprietary Information”),
ARUP may redact such ARUP Proprietary Information from the copies provided to ArQule; provided, that, ARUP shall not redact such
ARUP Proprietary Information to the extent that such information is required by ArQule for regulatory, patent application and/or
patent prosecution purposes. ARUP shall retain originals of all such records for a period of *** years, or as otherwise required
by Applicable Laws, whichever is longer. In no event will ARUP dispose of any such records without first giving ArQule*** days’
prior written notice of its intent to do so; provided, that, ARUP may, retain copies of any records as are reasonably necessary
for regulatory or insurance purposes, subject to ARUP’s obligations of confidentiality under this Agreement. ArQule will
reimburse ARUP for the reasonable costs and expenses incurred by ARUP for the copying and shipping of such records to ArQule.
In the event ARUP generates or receives records related to the conduct of a clinical study during the term of this Agreement or
any Scope of Work, ARUP will retain all such records for the longer of *** years following the completion of the clinical study,
or *** years following the last approval of a marketing application in an ICH region, unless a longer retention period is required
by applicable law. If ARUP is or becomes unable to comply with this retention period, ARUP will notify ArQule in writing and shall
make such records accessible for ArQule’s review and collection

 

2.8           Reports.
ARUP shall keep ArQule regularly informed of the progress of the Project. Without limiting the generality of the foregoing and
unless otherwise provided in a Scope of Work, ARUP shall promptly, not less than *** during the Term (and more frequently if required
to keep ArQule sufficiently informed), provide ArQule with (a) reports in reasonable detail regarding the status of ARUP’s
conduct of the Services, (b) all not previously reported Results, Inventions and original works of authorship generated, conceived,
developed and/or reduced to practice in the performance of the Services and (c) such supporting data and information as may be
reasonably requested from time to time by ArQule regarding the Project (each such report, a “Report”).

 

    	 	Page 7 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

2.9           Facility
Visit. ArQule’s representatives may, upon reasonable prior written notice, visit the ARUP facility with reasonable frequency
during normal business hours, and subject to ARUP’s policies and practices related to visitors to ARUP facilities to discuss
the progress of the Services and ARUP’s compliance with the terms of this Agreement. Any information disclosed to ArQule
representatives in writing, orally or by inspection of tangible objects in connection with any such visit shall be considered
Confidential Information of ARUP and protected as such by ArQule pursuant to the terms of this Agreement. Notwithstanding the
foregoing, except as otherwise agreed by the Parties in any Scope of Work, absent
the prior written approval of
ARUP, the number of such visits shall be limited to no more than *** per calendar year; shall not span more than *** consecutive
business days; and the number of ArQule representatives onsite during such visits shall exceed no more than ***
at any given time.

 

3.          Independent
Contractor Relationship; Certain Liabilities; Taxes; Subcontracting. 

 

3.1           Independent
Contractor. ARUP represents and warrants that it is an independent contractor and not the agent, employee, or franchisee of
any other entity. This Agreement does not constitute a hiring by either Party and nothing in this Agreement shall be interpreted
or construed as creating or establishing the relationship of employer and employee between ArQule and ARUP, or any person providing
the Services on behalf of ARUP. It is the Parties’ intention that ARUP have an independent contractor status and that ARUP
and its employees, independent contractors, advisors or Affiliates (hereafter, collectively, “ARUP’s Workers”)
shall not be considered ArQule employees for any purposes, including, but not limited to, the application of the Federal Insurance
Contribution Act, the Social Security Act, the Federal Unemployment Tax Act, the provisions of the Internal Revenue Code, any
applicable State Revenue and Taxation Code pertaining to income tax withholding at the source of income, and the Workers’
Compensation Insurance Code. This Agreement does not create or evidence any joint venture or partnership of the Parties. ArQule
shall not be liable for any obligations incurred by ARUP unless specifically authorized in writing. Neither Party shall have any
authority to incur, create or assume any liability or any other obligation, express or implied, in the name of, or on behalf of,
the other Party.

 

3.2           Waiver
of Benefits. ARUP, on behalf of ARUP and ARUP’s Workers, hereby waives
and foregoes any right to receive benefits given by ArQule to its regular employees, including, but not limited to health insurance,
paid vacation, sick leave, profit sharing or 401(k) plan benefits, stock distributions or any other ArQule employee benefit. ARUP
is solely responsible for the provision of benefits to ARUP’s Workers. This Section 3.1 is effective independently of the
employment status of ARUP or ARUP’s Workers as adjudged for taxation purposes or for any other purpose.

 

3.3           Taxes/Withholding.
ARUP acknowledges that no income, social security or other taxes shall be withheld or accrued by ArQule for the benefit
of ARUP or ARUP’s Workers. ARUP will be solely responsible for all employment insurance and taxes, licensing requirements,
government approvals and filings, or any other registration, authorization or permit required in connection with the performance
of its obligations hereunder. ARUP is solely responsible for determining and fulfilling ARUP’s Federal and State tax obligations
including the filing of tax returns and payment of taxes in accordance with the applicable provisions of Federal and State law.
ARUP is solely responsible for determining and fulfilling any income tax, social security, workers compensation, and any other
employment-related obligation related to ARUP’s engagement of ARUP’s Workers.

 

    	 	Page 8 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

3.4           Persons
Hired by ARUP. ARUP shall be solely responsible for hiring, supervising, directing and managing all persons, except for Approved
Subcontractors (as defined in Section 3.4, below), needed to provide the Services and perform the tasks and duties necessary to
complete the Deliverables described in the operative Scope of Work.

 

3.5           Subcontracting.
ARUP may not subcontract with another business or individual to perform a portion or portions of the Services without the
prior written approval of ArQule, which approval shall not be unreasonably withheld (each, an “Approved Subcontractor”);
provided, that, ARUP may subcontract and perform the Services or any part of the Services through the efforts of one or more of
ARUP’s medical directors, who are employees of the University of Utah. The approval by ArQule of any Approved Subcontractor
shall not release ARUP from any responsibility or liability in connection with said Approved Subcontractor and shall not create
a contractual or employment relationship between ArQule and the Approved Subcontractor. ARUP shall be responsible for the oversight
and supervision of the work and designated activities of each Approved Subcontractor, including assuring compliance with applicable
terms of this Agreement. ARUP shall ensure that all Approved Subcontractors comply with ARUP’s obligations under this Agreement
including, but not limited to, ARUP’s obligations concerning confidentiality and ownership of intellectual property. ArQule
shall have no obligation or liability to the Approved Subcontractor under this Agreement and the Approved Subcontractor shall
have no rights or remedies against ArQule under this Agreement or otherwise. ArQule may, at its discretion and upon request by
ARUP, directly pay an Approved Subcontractor for any Services performed pursuant to this Agreement and offset the amount of such
payment against any amount owed to ARUP.

 

3.6           Licenses
and Access to Third Party Technology. In the event ARUP concludes, in ARUP’s reasonable discretion, that it is necessary
to obtain and maintain a license(s) or other rights for ARUP to access or use any third-party Intellectual Property for the development,
manufacture, use or commercialization of the Companion Diagnostic (“ARUP Third Party Intellectual Property”),
ARUP will have the right, in its discretion, to negotiate a license to such ARUP Third
Party Intellectual Property; provided, that, (a) to the extent that any such license agreement requires (or would be reasonably
expected to require) ARUP to pay consideration greater than $*** in any one calendar year and (b) ARUP wishes to have ArQule reimburse
ARUP for such consideration, ARUP shall (i) regularly inform ArQule with respect to the negotiation status of such license agreement,
(ii) reasonably consult with ArQule regarding the terms of such license agreement, (iii) reasonably consider any comments from
ArQule on the terms of such license agreement; (iv) obtain
ArQule’s written approval of such terms before executing such license
agreement; and (v) subject to the foregoing, ArQule shall reimburse ARUP for the consideration
paid by ARUP under any such license agreement. ARUP shall not be held responsible to
the extent that ARUP is unable to obtain rights to any such ARUP Third Party Intellectual Property from the controlling
third parties under economically reasonable conditions.

 

4.          Compensation

 

4.1           Fees.
Subject to the terms and conditions of this Agreement, ArQule shall pay ARUP the fees specified in each Scope of Work (“Fees”),
along with Expenses, as set forth below, as ARUP’s sole and complete compensation for all Services, Deliverables, and Intellectual
Property rights provided by ARUP under this Agreement. Unless otherwise set forth in a Scope of Work, ARUP shall invoice ArQule
within *** days of the end of each month for Services provided in such month. All invoices will be addressed and sent to: Accounts
Payable, ArQule, Inc., One Wall Street, Burlington, MA 01803 or via such other method as may reasonably be requested by ArQule,
including electronic invoicing and payment systems. Each invoice will include a written description of the invoiced Services with
such specific detail as may be reasonably requested by ArQule. The invoice submitted by ARUP pursuant to this Section 4 shall
also include a detail of all reimbursable Expenses incurred during the period covered by such invoice as described in Section
4.2.

 

    	 	Page 9 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

4.2           Expenses.
 Solely to the extent described in the applicable Scope of Work, ArQule shall reimburse ARUP for any reasonable expenses for
travel undertaken at ArQule’s request, and other out-of-pocket expenses previously approved by ArQule, that are incurred
by ARUP or any of its employees in performing the Services (the “Expenses”), on the condition that ARUP provides
ArQule with invoices for such Expenses and adequate supporting documentation for such invoices.

 

4.3           Payments.
Unless otherwise expressly provided in the applicable Scope of Work, payment to ARUP of all undisputed invoiced Fees and Expenses
shall be due within *** days following ArQule’s receipt of the invoice for such Fees and Expenses submitted by ARUP pursuant
to Section 4.1 or 4.2 above. Payments shall be addressed to:

 

ARUP
Laboratories Inc.

Attn:
Yurika Oktavianna

500
Chipeta Way, Mail code #133

Salt
Lake City, UT 84108

Tel:
(801) 583-2787 ext. 2194

Email:
yurika.oktavianna@aruplab.com

 

ARUP
Tax Identification Number: 87-0403206

 

4.4           Disputed
Amounts. For disputed invoices or the disputed portion of an invoice, ArQule shall use reasonable efforts to provide to ARUP,
in writing, within *** business days, justification for the withheld payment. In the event the Parties mutually determine that
a disputed amount was properly invoiced by ARUP, ArQule will promptly pay the disputed amount without additional invoicing by
ARUP. ArQule and ARUP shall negotiate in a timely, good faith manner to resolve billing queries.

 

5.          Audits

 

5.1           Financial
Audit and Record Keeping. ARUP shall keep full and accurate records and accounts of all its Service Fees and Expenses incurred
in connection with this Agreement. All records demonstrating ARUP’s performance under this Agreement, including but not
limited to ARUP’s and any authorized Approved Subcontractors’ invoices, shall be available for inspection and audit
by ArQule or any independent auditors designated by ArQule at all reasonable times and upon reasonable notice during the Term
of the Agreement and for *** years thereafter (“Financial Records and Accounts”) solely for the purpose of
confirming ARUP’s performance under this Agreement. Upon request by ArQule and subject to ARUP’s policies and practices
related to visitors to ARUP facilities, ARUP shall allow ArQule or ArQule’s authorized representatives, at ArQule’s
sole expense, to visit ARUP's facilities during normal business hours to review the Financial Records and Accounts and/or to make
copies of relevant records.. If ArQule discovers that ARUP has been overcharging ArQule as a result of such audit, ARUP will refund
the amount of any overcharging that is not disputed in good faith by ARUP within *** days after ArQule’s demand therefor.
All Financial Records and Accounts shall be deemed Confidential Information of ARUP.

 

    	 	Page 10 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions. 

 

5.2           Regulatory
Inspections. ARUP shall promptly notify ArQule upon becoming aware of any
regulatory inspections by a duly authorized representative (“Inspector”) of any Regulatory Authority, including,
without limitation, the FDA, of which it becomes aware and which directly relate to the Services or Deliverables to be provided
under a Scope of Work. ARUP shall provide ArQule with the following data as soon as practicable: (a) the inspecting entity and
the purpose of the inspection, (b) the name and credential number of the Inspector, and (c) a copy of the form(s) issued by the
Inspector, if any. In the event that ArQule believes that such inspection is not required by Applicable Laws or an accrediting
or licensing entity providing approval, licensure, or accreditation to ARUP and and/or that the conduct of such inspection would,
if permitted by ARUP, constitute a breach of ARUP’s confidentiality obligations under this Agreement, ArQule shall notify
ARUP of ArQule’s determination sufficiently in advance of such inspection that ARUP can notify the inspecting authority
of ArQule’s objection. ArQule will reasonably cooperate with ARUP in enabling ARUP to communicate ArQule’s objection
to such inspection. ARUP shall have the primary responsibility for preparing any responses relating to the Materials and/or Services
that may be required by the inspecting entity, but ArQule will provide reasonable assistance, at ArQule’s expense, in aiding
ARUP with respect to such responses. ARUP will consult with ArQule regarding any response to an inspecting entity relating to
the Materials and/or Services. ARUP shall keep ArQule informed on such inspection and shall provide ArQule with copies of all
correspondence, received or generated pursuant to any such inspection. Materials, forms and records associated with such inspection
will be made available to ArQule at ARUP’s premises or via webinar. Unless prohibited by Applicable Laws, ArQule shall have
the right to be present at any such inspections, and where not prohibited by Applicable Laws, shall be present at such inspections.
ARUP shall take any reasonable and necessary actions requested by ArQule to cure deficiencies as noted during any such inspection.

 

6.          Intellectual
Property

 

6.1           In
General.

 

6.1.1           Scope
of Work. The Parties hereby acknowledge and agree that (a) the rights and obligations
of the Parties under this Agreement with respect to intellectual property, including the ownership and use of any and all Inventions,
are set forth this Article 6; (b) while the Parties may from time to time supplement such rights and obligations in this Article
6 through a Scope of Work, such supplemental provisions shall apply only to the extent such provisions are not in conflict,
or inconsistent with this Article 6; and (c) in the event of any inconsistency between
this Article 6 and the intellectual property provisions in a Scope of Work, this Article 6 shall control.

 

    	 	Page 11 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

6.1.2           ArQule.
ArQule shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all ***.
In connection therewith, ARUP hereby assigns, and shall require its employees to assign, to ArQule, all right, title and interest
in and to all ***.

 

6.1.3           ARUP.
ARUP shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all ***.
In connection therewith, ArQule hereby assigns, and shall require its employees to assign, to ARUP, all right, title and interest
in and to all ***, subject to the license to ARUP Inventions granted to ArQule pursuant to Section 6.3.

 

6.1.4           Joint
Inventions. The Parties shall jointly own all Joint Inventions. Notwithstanding anything to the contrary contained
herein or under Applicable Laws, the Parties hereby agree that either Party may use, license or sublicense to Affiliates or Third
Parties all or any portion of its interest in the Joint Inventions for any purposes without the prior written consent of the other
Party, without restriction and without the obligation to provide compensation to any other Party.

 

6.2           Patent
Prosecution. ArQule shall be responsible, acting through patent counsel of its choice, for the filing, prosecution
and maintenance of any Patent applications and Patents claiming or covering any ***, and ARUP shall be responsible, acting through
patent counsel of its choice, for the filing, prosecution and maintenance of any Patent applications and Patents claiming or covering
any ***; provided, that, nothing in this Agreement shall be construed as requiring either Party to file, prosecute, or a maintain
a patent for an Invention Controlled by that Party. Each Party shall reasonably cooperate with the
other Party in connection with the same, including, upon the request of the
prosecuting Party, promptly executing any and all Patent applications, formal documents, assignments, or other instruments
which the prosecuting Party deems necessary or reasonably useful for the filing,
prosecution and/or maintenance of any Patent applications or Patents claiming or covering any such Inventions

 

6.3           Cooperation.
During the Term of this Agreement, ARUP shall provide reasonable cooperation to ArQule
and its attorneys and agents in the preparation and filing of all papers and other documents as may be required to obtain, perfect,
sustain and enforce ArQule’s rights in and to any ***, including but not limited to, joining in any proceeding to obtain
letters, patents, copyrights, trademarks or other legal rights with respect to any such *** in the United States and in any and
all other countries; provided, that, ArQule shall bear the expense of such proceedings. Any patent or other legal right with respect
to any *** issued to ARUP personally shall be assigned by ARUP to ArQule without charge by ARUP. In the event ArQule is unable
for any reason, after reasonable effort, to secure ARUP’s signature on any document needed in connection with the actions
specified in this Section 6.3, ARUP hereby irrevocably designates and appoints
ArQule and its duly authorized officers and agents as its agent and attorney in fact, which appointment is coupled with an interest,
to act for and on its behalf, for the express and sole purpose to execute, verify and file any such documents to further the purposes
of this Section 6.3 with the same legal force and effect as if executed by ARUP.

 

    	 	Page 12 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

6.4           Joint
Invention Patents. Promptly after the determination that any Invention is a Joint
Invention, the Parties will determine which Party (the “Prosecuting Party”) will undertake the filing, prosecution
and maintenance of Patents covering such Joint Invention (“Joint Invention Patent”) with respect thereto, based
on the respective expertise of the Parties. If the Parties fail to agree, the filing, prosecution and maintenance of such Joint
Invention Patent shall be jointly controlled by the Parties, using patent counsel agreed upon by the Parties. All patent costs
incurred in connection with the preparation, filing, prosecution and maintenance of a Joint Invention Patent shall be shared equally
by the Parties. If one Party (the “Assigning Party”) is not interested, or not willing to equally share the
related patent costs, with respect to any such Joint Invention Patent in a given country, then: (a) the other Party shall become
the Prosecuting Party upon giving notice to the Assigning Party of its intention to continue to seek rights for such Joint Invention
Patent, (b) upon receiving written notice from the Prosecuting Party, the Assigning Party shall assign all of its rights in the
Joint Invention Patent to the Prosecuting Party, and (c) the Prosecuting Party shall at its own cost and expense, file for, prosecute
and maintain such Joint Invention Patent in such country in the Prosecuting Party’s own name. For all Joint Invention Patents
for which the Parties are sharing costs, the Prosecuting Party shall keep the other Party reasonably informed of prosecution
activities with respect to the Patent application for a Joint Invention Patent. The
Prosecuting Party shall provide the other Party with a copy of material
communications from any Patent authority regarding such Joint Invention Patents,
and shall provide drafts of any material filings or responses to be made to such Patent authorities a reasonable amount of time
in advance of submitting such filings or responses so that the other Party may
have an opportunity to review and comment.

 

6.5           Project
Results. Ownership of Project Results shall be determined as follows: (a) ArQule shall own all Project Results that relate
to *** (“Patient-Related Project Results”) (the “ArQule Project Results”) and
(b) ARUP shall own all Project Results, other than Patient-Related Project
Results, that relate to *** (“ARUP Project Results”), the PDP and (c) all other Project Results,
including the Project Results, other than Patient-Related Project Results, that would consist of, constitute or relate to information
that falls within both subsections (a) and (b) above shall be jointly owned by the Parties (“Joint Project Results”),
and each Party shall have the right to use such Joint Project Results for any and all purposes.

 

6.6           License
Grant to ARUP. ArQule hereby grants to ARUP a fully paid, non-exclusive license under any and all ArQule Background Know-How
and ArQule Background Patents to the extent necessary for ARUP to conduct the Services during the Term.

 

6.7           License
Grant to ArQule. If any ARUP Invention is employed by, is embodied within, or otherwise materially useful or necessary to
use or to practice, any ***, ARUP shall be deemed to have granted, and hereby grants, to ArQule a non-exclusive, worldwide, royalty-free,
fully-paid, sublicensable, perpetual license under such ARUP Invention solely to the extent necessary to use such *** and/or practice
such ***.

 

    	 	Page 13 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

7.          Confidentiality

 

7.1           Confidential
Information Except to the extent expressly authorized by this Agreement or by the disclosing Party in writing, during the
Term and for *** years thereafter, a Receiving Party shall maintain the Confidential Information of the Disclosing Party in strict
trust and confidence and shall disclose such Confidential Information only to its Representatives and use such Confidential Information
only for the purposes provided for in this Agreement. The term “Representatives” shall mean a Party’s
directors, officers, employees, agents, subcontractors, representatives, or other individuals or entities controlled by that Party.
Without limiting the foregoing, (a) ARUP may use the Confidential Information
received from ArQule only to the extent required to perform the Services and (b) either
Party may use the Confidential Information received from the other Party to perform its obligations or to exercise its
rights under this Agreement, or for the purpose of determining the receiving Party’s rights and obligations with respect
to such information or this Agreement, and for no other purposes. Neither Party shall use the Confidential Information for any
purpose or in any manner that would constitute a violation of Applicable Laws. This Agreement hereby expressly supersedes any
previous agreements between the parties with respect to use or disclosure obligations that might otherwise apply to any information
that may be exchanged pursuant to this Agreement.

 

7.2           Additional
Agreements. Each Receiving Party shall ensure that each of its Representatives who will have access to any Confidential Information
of the Disclosing Party or perform any Services is under confidentiality and non-use
obligations with respect to the Disclosing Party’s information no less stringent than those set forth herein.

 

7.3           Exceptions.
The obligations of confidentiality and nonuse set forth in Section 7.1 shall not apply to any specific portion of information
that the Receiving Party can demonstrate by competent written proof: (a) is in the public domain or comes into the public domain
through no fault of the Receiving Party; (b) is furnished to the Receiving Party by a third party that the Receiving Party does
not know is subject to a duty of confidentiality with respect thereto; (c) is already known by the Receiving Party at the time
of receiving such Confidential Information; or (d) is independently developed by the Receiving Party without access to or use
of the Confidential Information of the Disclosing Party.

 

7.4           Authorized
Disclosure. Notwithstanding the foregoing in this Section 7, a Receiving Party may disclose Confidential Information of the
Disclosing Party to the extent such disclosure is required by Applicable Laws, or pursuant to a valid order of a court or other
governmental body having jurisdiction, provided that the Party required to make such disclosure provides the other Party
with reasonable prior written notice of such disclosure and reasonable assistance in obtaining a protective order or confidential
treatment preventing or limiting the disclosure and/or requiring that the Confidential Information so disclosed be used only for
the purposes for which the Applicable Laws require, or for which the order was issued.

 

7.5           Publication;
Use of Names.

 

7.5.1           Publication
of Results- in General. Under no circumstances may either Party use the name of the other Party or any of its personnel in
any publication or any form of advertising without such other Party’s prior written consent, except as necessary to comply
with applicable law or regulations. For the avoidance of doubt, neither Party shall disclose, present, disseminate or produce
any publication that contains information regarding the Services, Deliverables or any Confidential Information of the other Party
without such other Party’s prior written consent except as provided in this Section 7.5. ArQule will have
the sole right to make, be responsible for, and control the timing and
scope of, any publication, presentation or use, including for non-confidential
discussions with a Third Party (each, a “Publication”) of ArQule Project
Results and ARUP will have the sole right to make, be responsible for
and control the timing and scope of any Publication of ARUP Project Results.
ArQule and its Affiliates shall not publish, present or use ARUP Project Results
or any portion thereof for any Publication without ARUP’s prior written consent, and ARUP and its Affiliates shall not publish,
present or use ArQule Project Results or any portion thereof for any Publication
without ArQule’s prior written consent.

 

    	 	Page 14 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

7.5.2           Publication
of Joint Project Results. Any Publication of any Joint Project Results must be agreed and approved by both Parties. All
Publications that include Joint Project Results shall be subject to the provisions of this Agreement relating to confidentiality
and non-disclosure. At least *** days prior to submission of a Publication that includes Joint Project Results, the publishing
Party shall submit to the other Party for review any proposed Publication. The other Party may review the proposed Publication
and shall provide comments (if any) to the publishing Party no later than *** days prior to the proposed submission date for the
Publication. Upon notice to the publishing Party that the other Party reasonably believes that one or more Patent applications
should be filed to claim Inventions owned by the other Party (or Joint Inventions) prior to any Publication, the publishing Party
shall delay the submission or disclosure of the Publication until such Patent application(s) have been filed; provided, that,
the other Party expeditiously files any such Patent application(s); and, provided, further, that, any such delay of disclosure
or submission of a Publication will not exceed *** days from the date of receipt of such notice by the publishing Party. If the
other Party believes that any Publication contains Confidential Information belonging to the other Party, the other Party will
notify the publishing Party, which will remove all references to such Confidential Information prior to publication, presentation
or use. Notwithstanding the foregoing, to the extent ArQule reasonably determines
that the Publication of data or results that constitutes Joint Project Results is necessary to accurately present the results
of any clinical trial, it shall have the right to make such Publication upon written notice to ARUP but without ARUP’s prior
written consent.

 

7.6           Return
of Confidential Information. Upon termination or expiration of the Agreement, or upon written request of the disclosing Party,
the Receiving Party shall promptly return or destroy all documents, notes and other tangible materials representing the Disclosing
Party’s Confidential Information and all copies thereof; provided, however, that the Receiving Party may retain a single
archival copy of the Confidential Information for the sole purpose of facilitating compliance with the surviving provisions of
this Agreement. The foregoing obligation to return or destroy Confidential Information shall not apply to Confidential Information,
such as that stored in routine electronic backups, the destruction or return of which is economically or technologically infeasible.

 

7.7           Injunctive
Relief. The Parties expressly acknowledge and agree that any breach or threatened breach of this Section 7 by one Party may
cause immediate and irreparable harm to the other Party that may not be adequately compensated by damages. Each Party therefore
agrees that in the event of such breach or threatened breach by a Party, and in addition to any remedies available at law, the
non-breaching Party shall have the right to seek equitable and injunctive relief, without bond, in connection with such a breach
or threatened breach.

 

    	 	Page 15 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

8.          Representations
and Warranties

 

8.1           Due
Authorization. Each Party represents and warrants that (a) it has the full power and authority to enter into this Agreement,
(b) this Agreement has been duly authorized, and (c) this Agreement is binding upon it.

 

8.2           No
Inconsistent Obligations or Constraints upon ARUP. ARUP represents and warrants that (a) it is qualified and permitted to
enter into this Agreement; (b) the terms of the Agreement are not inconsistent with its other contractual arrangements; (c) it
has the right to grant all licenses granted to ArQule in this Agreement; and (d) it shall perform the Services in accordance with
the highest standards of care and diligence practiced by recognized firms in providing services of a similar nature.

 

8.3           No
Debarred Person. Neither ARUP nor any of ARUP’s Workers is debarred pursuant to the Generic Drug Enforcement Act of
1992, 21 U.S.C. §335a, as amended, or any similar state law or regulation (collectively “Debarred”), excluded
by the Office of Inspector General pursuant to 42 U.S.C. § 1320a-7, et seq. or any state agency from participation
in any federal or state health care program (collectively “Excluded”) or otherwise disqualified or restricted
by the FDA pursuant to 21 C.F.R. 312.70 or any other Regulatory Authority (collectively “Disqualified”). ARUP
further represents and certifies that, to the best of ARUP’s actual knowledge as of the date of execution of this Agreement,
after due inquiry, ARUP, its employees and ARUP’s Workers are not under investigation or otherwise aware of any circumstances
which may result in ARUP being Debarred, Excluded or Disqualified. ARUP further represents and certifies that it shall not employ
or otherwise use any business or individual that is Debarred, Excluded or Disqualified to perform any portion or portions of the
Services hereunder. ARUP further represents and certifies that in connection with the subject matter of this Agreement: (i) none
of its ARUP, Its employees or ARUP Workers is a Foreign Official as defined in the U.S. Foreign Corrupt Practices Act, (ii) it
will not make, accept or request any payment, either directly or indirectly, of money or other assets to any third party where
such payment would constitute violation of any law, including the U.S. Foreign Corrupt Practices Act and the UK Bribery Act 2010,
(iii) regardless of legality, it shall neither make, accept nor request any such payment for the purpose of improperly influencing
the decisions or actions of any third party, and (iv) it shall report any suspected or actual violation of this Section 8.3 to
ArQule upon becoming aware of the same. During the term of this Agreement, ARUP shall immediately notify Sponsor in writing, pursuant
to the Notice provisions provided herein, of any change in the status of any representation or certification set forth in this
Section 8.3.

 

8.4           No
Infringement. ARUP’s performance of the Services under this Agreement shall not, to the best of ARUP’s knowledge,
infringe the intellectual property rights of a third party. In performing the Services, neither ARUP nor any of ARUP’s Workers
shall knowingly make any unauthorized use of any confidential or proprietary information of any other party or knowingly infringe
the intellectual property rights of any other party.

 

8.5           Deliverables.
The Services performed and the Deliverables shall conform to the Specifications, requirements, and other terms in the applicable
Scope of Work and this Agreement. In the event that the Services performed and/or the Deliverables do not conform to the Specifications,
requirements, and other terms in the applicable Scope of Work and this Agreement, without limiting any other rights or remedies
ArQule may have, ARUP will cooperate with ArQule to identify the failure of conformity and to correct such failure at no additional
charge to ArQule. If the breach has not been fully cured within *** days after ARUP received notice thereof (or such longer period
of time as ArQule may, in its discretion, give ARUP to cure the breach, by written notice to ARUP), (a) ARUP will refund all Fees
and Expenses previously pre-paid to ARUP for any milestones yet to be achieved under the applicable Scope of Work, and (b) ArQule
will have the right, in its discretion, to terminate the applicable Scope of Work and/or this Agreement upon written notice on
the expiration of such ***-day period.

 

    	 	Page 16 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

8.6           Warranty
Disclaimer. EXCEPT AS EXPLICITLY SET FORTH IN THIS SECTION 8, EACH PARTY HEREBY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. ASIDE FROM THE
ASSURANCES SET FORTH IN SECTION 8.5 REGARDING THE PARTIES’ COOPERATION TO OBTAIN DESIRED FUNCTIONALITY WITH RESPECT TO THE
DELIVERABLES, ARUP SPECIFICALLY DISCLAIMS ANY WARRANTY WITH RESPECT TO THE FUNCTIONALITY OR PERFORMANCE OF ANY DELIVERABLES AND
FURTHER DISCLAIMS ANY ASSURANCE THAT THE DELIVERABLES WILL MEET ANY STANDARDS NECESSARY FOR APPROVAL BY THE FDA OR ANY OTHER REGULATORY
BODY.

 

9.          Insurance.
Throughout the term of this Agreement, ARUP and ArQule shall each secure and maintain,
where appropriate, on an occurrence basis, commercial general liability insurance, professional liability insurance, employers
liability insurance, and such other insurance coverage, in forms and amounts as may be reasonable and appropriate in the performance
of the obligations assumed hereunder but in no event with limits less than $*** per occurrence and $*** annual aggregate. Each
Party shall also secure and maintain workers compensation in accordance with all applicable statutory requirements. Upon request,
each Party shall provide to the other certificates of proof of the required insurance coverage. Each Party shall indemnify and
hold harmless the other Party from any claims which may arise as a result of the Party’s failure to provide any of the insurance
coverage required herein. ARUP and ArQule may self-insure all or any of these required coverages.

 

10.         Indemnification;
Limitation of Liability

 

10.1         By
ARUP. ARUP shall indemnify, defend and hold harmless ArQule and its affiliates and their respective directors, officers, employees,
and agents (the “ArQule Indemnitees”) from and against any and all costs, expenses, liabilities, damages, losses
and harm (including reasonable legal expenses and attorneys’ fees) arising out of or resulting from any third party suits,
claims, actions, or demands (collectively, “Claims”) to the extent caused by: (a) breach of this Agreement
by ARUP in its performance of obligations hereunder; (b) the negligence of ARUP or its officers, directors, employees, or agents
within the course and scope of their employment; (c) ARUP’s material breach of its warranties, or representations under
this Agreement; except in each case to the extent that a Claim arises out of
or results from the negligent acts or intentional omissions of any ArQule Indemnitee or ArQule’s breach of its obligations,
warranties, or representations under this Agreement.

 

    	 	Page 17 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

10.2         By
ArQule. ArQule shall indemnify, defend and hold harmless ARUP and its directors, officers, employees, and agents (the “ARUP
Indemnitees”) from and against any and all Claims to the extent resulting from or caused by: (a) breach of this Agreement
by ArQule in the performance of its obligations hereunder; (b) the negligence of any ArQule Indemnitee within the course or scope
of their employment; or (c) ArQule’s material breach of its warranties or representations under this Agreement; (d) the
actual or alleged infringement of any Patents of any Third Party as a result of the use by ARUP of ArQule Background Know-How
or ArQule Background Patents in the conduct of the Services in accordance with any Scope of Work; or
(e) the actual or alleged infringement of any Intellectual Property of any Third Party as a result of the use by ARUP of the Supplier
*** to develop and commercialize the Companion Diagnostic assay in the United States as contemplated by this Agreement, except
in each case to the extent that a Claim arises out of or results from the negligent acts or intentional omissions of any ARUP
Indemnitee or ARUP’s modification of ArQule IP or ARUP’s breach
of its obligations, warranties, or representations under this Agreement.

 

10.3         Indemnification
Conditions and Procedures. Each Party’s agreement to indemnify, defend and hold harmless the other Party is conditioned
on the indemnified Party: (i) providing written notice to the indemnifying Party of any claim or demand for which is it seeking
indemnification hereunder promptly after the indemnified Party has knowledge of such claim; (ii) permitting the indemnifying party
to assume full responsibility to investigate, prepare for and defend against any such claim or demand, except that the indemnified
Party may cooperate in the defense at its expense using its own counsel; (iii) assisting the indemnifying Party, at the indemnifying
Party’s reasonable expense, in the investigation of, preparing for and defense of any such claim or demand. Neither Party
may enter into any non-monetary compromise or settlement, consent judgment or other voluntary final disposition of any such claim
or demand without the indemnifying Party’s written consent, such consent not to be unreasonably withheld or delayed.

 

10.4         Defense
of Certain Infringement Claims. In the event that any action, suit or proceeding is brought against ARUP alleging the
infringement of the Intellectual Property of any Third Party by reason of the use by ARUP of the Supplier *** to develop and commercialize
the Companion Diagnostic assay in the United States as contemplated by this Agreement, ARUP shall notify ArQule promptly upon
the earlier of (a) receipt of service of process in such action, suit or proceeding or (b) the date on which ARUP becomes aware
that such action, suit or proceeding has been instituted. ArQule shall have the sole right to defend such action, suit or proceeding
at its sole expense, the Supplier shall have the right to separate counsel at its own expense in any such action, suit or proceeding
and the Parties shall cooperate with each other in all reasonable respects in any such action, suit or proceeding. ArQule will
have the sole right to settle or otherwise resolve any such action, suit or proceeding without ARUP’s prior written consent,
provided that such settlement does not admit fault on the part of ARUP or result in any monetary liability on the part of ARUP.
Any settlement costs and/or royalties paid in settlement of any such suit, and the payment of any damages to the Third Party,
shall be borne solely by ArQule. In the event ArQule concludes, in its sole discretion, that it is unable to settle or otherwise
resolve any such action, including by obtaining a license from the relevant Third Party, ArQule may terminate this Agreement by
providing written notice to ARUP.

 

10.5         Limitation
of Liability. EXCEPT FOR DAMAGES AVAILABLE FOR BREACHES OF CONFIDENTIALITY OBLIGATIONS UNDER SECTION 7, AND THE INDEMNIFICATION
RIGHTS AND OBLIGATIONS UNDER SECTION 10, (A) NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL, PUNITIVE OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF
THE POSSIBILITY OF SUCH DAMAGES; AND (B) NEITHER PARTY’S AGGREGATE LIABILITY TO THE OTHER FOR ANY MATTERS OR CLAIMS ARISING
OUT OF THIS AGREEMENT OR THE SERVICES, OTHER THAN A CLAIM FOR FAILURE TO PAY AMOUNTS OWED, SHALL EXCEED ***.

 

    	 	Page 18 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

11.         Term
and Termination

 

11.1         Term.
Subject to the provision for early termination set forth below in Section 11.2 of this Agreement, this Agreement shall commence
as of the Effective Date and shall continue for *** years from the Effective
Date (the “Term”), provided that the terms of this Agreement shall continue to apply to any Scope of Work entered
into prior to the expiration of the Term that expires after the Term. This Agreement will automatically be renewed for *** year
if not terminated in writing by either Party within *** days of the termination
date, and may be renewed for successive years if no written request for termination is sent by either Party to
the other Party.

 

11.2         Termination.

 

11.2.1           Termination
for Material Breach. In the event that either Party materially breaches its obligations as required hereunder, the other Party
shall have the right to terminate this Agreement upon *** days’ prior written notice to the defaulting Party specifying
the default; provided, however, if said defaulting Party cures the default within the said *** day period, this Agreement shall
continue in full force and effect as if no default had occurred. For clarity, a breach that is specific to a Scope of Work shall
not serve to terminate this Agreement, but shall be addressed as set forth below. Any termination of this Agreement shall automatically
terminate any Scopes of Work or related agreements that may be in effect, unless the Parties agree otherwise in writing. Either
Party may terminate a Scope of Work upon *** days’ notice if the other party commits a material breach of such Scope of
Work and fails to cure such breach within the notice period.

 

11.2.2           Termination
by ArQule. ArQule may terminate this Agreement upon written notice to ARUP pursuant
to Section 10.4 or upon *** days’ prior written notice to ARUP in the event of a Drug Development Failure.

 

11.3         Effects
of Termination

 

11.3.1           Survival.
Sections 1, 2.6, 2.7, 3.1, 3.2, 3.3, 3.4, 5.1, 6 (other than Section 6.6), 7, 9, 10 (solely to the extent the Claims can be
attributed to action or omission during the Term), 11.3 and 12 shall survive any termination or expiration of this Agreement.
Termination or expiration of this Agreement shall not affect either Party’s liability for any breach of this Agreement it
may have committed before such expiration or termination.

 

11.3.2           Return
of ArQule Property. Upon the termination of this Agreement for any reason and written request by either Party, ArQule or ARUP,
as the case may be shall return or destroy the Materials provided by the other Party under this Agreement, and return to the other
Party, or destroy, such other Party’s Confidential Information, as set forth herein, unless the applicable Scope of Work
or an applicable materials transfer agreement between the parties expressly provides otherwise.

 

    	 	Page 19 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

11.3.3           Compensation.
 Upon the expiration or termination of this Agreement or a Scope of Work, unless the applicable Scope of Work expressly provides
otherwise, ArQule will pay ARUP Fees reflecting the amounts owed for Services that are completed in accordance with this Agreement
prior to the effective date of such termination and the Results or Deliverables thereof delivered to ArQule. ArQule shall also
reimburse ARUP for non-cancellable Expenses incurred by ARUP with respect thereto before the effective date of such termination.

 

12.         General
Provisions

 

12.1         Governing
Law. This Agreement is made under and shall be construed according to the laws of the State of Delaware without regard to
any conflict of law principles that would provide for the application of the law of another jurisdiction.

 

12.2         Severability.
If any provision of this Agreement should be held invalid or unenforceable, the remaining provisions shall be unaffected and
shall remain in full force and effect, to the extent consistent with the intent of the parties as evidenced by this Agreement
as a whole.

 

12.3         Force
Majeure.  If either Party hereto is prevented from carrying out its obligations under this Agreement by events beyond its
reasonable control, acts of God or government, natural disasters, including earthquakes or storms, fire, political strife, public
health emergencies, terrorism, failure or delay of transportation, then such Party’s performance of its obligations hereunder
shall be excused during the period of such events and for a reasonable period of recovery thereafter, and the time for performance
of such obligations shall be automatically extended for a period of time equal to the duration of such events; provided, however,
that the Party claiming force majeure shall promptly notify the other Party of the existence of such force majeure, shall use
commercially reasonable efforts to avoid or remedy such force majeure and shall continue performance hereunder with the utmost
dispatch whenever such force majeure is avoided or remedied. When such circumstances arise, the Parties shall discuss what, if
any, modification of the terms of this Agreement may be required in order to arrive at an equitable solution.

 

12.4         Resolution
of Disputes. 

 

12.4.1           In
General. The Parties shall first attempt to settle any and all disputes arising out of or in connection with or relating to
the execution, interpretation, performance, or nonperformance of this Agreement or any other certificate, agreement, or other
instrument between, involving, or affecting the parties (including the validity, scope, and enforceability of this agreement)
(each, a “Dispute”) through good faith negotiation before resorting to litigation. The Parties shall conduct
and complete such good faith negotiation involving substantive participation by senior management for each party within *** days
of a Dispute notice, which shall set forth the nature of any dispute between the Parties. All Dispute notices shall be sent in
accordance with the notice provision herein. Parties, upon written agreement, can adjust time limits within this Section 12.4.

 

12.4.2           Disputes
Under *** Supply Agreement. Notwithstanding anything to the contrary in this Agreement or in the *** Supply Agreement, any
Dispute that arises under the *** Supply Agreement shall be resolved in accordance with § 19 of the *** Supply Agreement,
subject to the following:

 

    	 	Page 20 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

(a)          Each
Party shall bear its own costs and expenses, including attorneys’ fees, in connection with any arbitration conducted under
§19 of the *** Supply Agreement; provided, that, (i) ArQule shall reimburse ARUP for the reasonable costs and expenses incurred
by ARUP in connection with any such arbitration, including ARUP’s reasonable attorneys’ fees and costs (collectively,
“ARUP Arbitration Costs”), solely to the extent that (A) the Dispute that is the subject of the arbitration
(1) is initiated by the Supplier and (2) does not involve a claim that arises out of, or results from, the alleged breach by ARUP
of this Agreement or the alleged negligent acts or intentional omissions of ARUP outside of the course of ARUP’s performance
under the *** Supply Agreement and (B) ARUP provides written notice to ArQule of any Dispute for which is it seeking reimbursement
promptly after ARUP has knowledge of such Dispute; and (ii) ArQule shall reimburse ARUP for ARUP Arbitration Costs to the extent
that the Dispute that is the subject of the arbitration is for any reason not covered by subsection (i), including any Dispute
that is being defended by ARUP in good faith; provided, that, ArQule’s obligation to reimburse ARUP for ARUP Arbitration
Costs under this Section 12.4.2(a) shall not exceed $*** in the aggregate.

 

12.5         No
Assignment. ARUP may not assign its rights or obligations under this Agreement without the prior written consent of ArQule,
which consent may be given or withheld in ArQule’s sole and absolute discretion; provided, that, ARUP may assign its rights
or delegate its obligations under this Agreement without such consent to (i) any Affiliate or (ii) its successor in interest in
connection with any merger, consolidation, or sale of all or substantially all of the assets of ARUP. ArQule may not transfer
or assign this Agreement or any Scope of Work, or any of its rights and obligations under this Agreement or any Scope of Work,
in whole or in part, without the consent of ARUP, provided that such consent shall not be unreasonably delayed, conditioned, or
denied. Notwithstanding the foregoing, ArQule may transfer or assign this Agreement or any Scope of Work, or any of its rights
and obligations under this Agreement or any Scope of Work, in whole in in part, (a) without the consent of ARUP to any: (i) Affiliate;
(ii) wholly owned subsidiary or successor in interest; (iii) any third party with which it merges, or consolidates, or to which
it transfers all or substantially all of its assets to which this Agreement relates and (b) with the prior written consent of
ARUP, which will not be unreasonably withheld to any third party licensee of ARQ 087. In the case of any permitted assignment
or transfer of or under this Agreement, this Agreement shall be binding upon and shall inure to the benefit of the respective
permitted successors and assigns of each of the Parties hereto (if any). No person who is not a Party shall have any rights hereunder
as a third-party beneficiary or otherwise.

 

12.6         Notices.
Each Party will deliver all notices or reports permitted or required under this Agreement in writing and will be sent by personal
delivery or reputable expedited delivery service with signature required. All such notices or reports will be deemed given upon
receipt or refusal of delivery. Such notices shall be addressed to the Party concerned at the addresses set forth below or at
such other addresses as may be furnished in writing to the other party hereto. Each Party may change its address for receipt of
notice by giving notice of such change to the other Party.

 

	If to ArQule:  	ArQule , Inc. 
	 	One Wall Street
	 	Burlington, MA 01803

 

    	 	Page 21 of 27	 

     

    

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

	 	Attention:  Ron Savage
	 	Title:  Senior Director, Preclinical Development
	 	Tel: 781-994-0300
	 	Email: rsavage@arqule.com
	 	Fax Number: 
	 	 
	 	With a copy to Peter S. Lawrence
	 	Email: plawrence@arqule.com
	 	 
	If to ARUP:	ARUP Laboratories Inc.
	 	500 Chipeta Way, Mail code #209
	 	Salt Lake City, UT 84108
	 	Attention:  Karen A. Heichman, PhD
	 	Director, PharmaDx
	 	Tel: (801) 584-5068
	 	Fax Number: (801) 584-5207

 

12.7         Remedies.
The rights and remedies provided to each Party in this Agreement are cumulative and in addition to any other rights and remedies
available to such Party at law or in equity.

 

12.8         Headings.
The headings and section identifiers contained in this Agreement are for convenience of reference only, shall not be deemed
to be a substantive part of this Agreement and shall not be referred to in connection with the construction or interpretation
of this Agreement.

 

12.9         Waiver.
All waivers must be in writing and signed by the Party to be charged. Any waiver or failure to enforce any provision of this
Agreement on one occasion will not be deemed a waiver of any other provision or of such provision on any other occasion.

 

12.10         Entire
Agreement; Amendments. This Agreement, including the Scopes of Work hereunder, constitutes the final, complete and exclusive
agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, communications,
negotiations or understandings between the Parties with respect to the matters addressed herein. No modification of or amendment
to this Agreement will be effective unless in writing and signed by all Parties.

 

12.11         Counterparts.
This Agreement may be executed in one or more counterparts (including by facsimile or .pdf), each of which shall constitute
an original and all of which, when taken together, shall constitute one agreement.

 

Signature Page to
Follow

 

    	 	Page 22 of 27	 

     

    

 

In
Witness Whereof, the Parties have executed this Master Services Agreement as of the Effective Date.

 

	ArQule, Inc.	 	ARUP Laboratories Inc.
	 	 	 
	Signed:	 	Signed:
	 	 	 
	 /s/ Peter S. Lawrence 	 	 
	Peter S. Lawrence	 	 /s/ Sherrie L. Perkins 
	President and Chief Operating Officer	 	Sherrie L. Perkins, MD, PhD
	 	 	 
	 	 	Senior Vice President
	 	 	 
	 	 	Director, Research & Development
	 	 	 
	 	 	Chief, Clinical Pathology

 

Signature Page to Master Services Agreement

 

    	 	Page 23 of 27	 

     

    

 

Exhibit
A

 

Form
Scope of Work

 

This Scope of Work is incorporated into
the Master Services Agreement dated [month] [day], [year] by and between ArQule and ARUP (for the purposes of this Scope of Work,
the “Agreement”). This Scope of Work describes Services and Deliverables to be performed and provided by ARUP
pursuant to the Agreement. In the event of any conflict between the Agreement and any provision of this Scope of Work, the Agreement
will control unless the Parties’ intent to alter the terms of the Agreement is expressly set forth in such provision, and
such alteration shall only apply to this Scope of Work and shall not be construed as an amendment to the terms of the Agreement.
All capitalized terms used and not expressly defined in this Scope of Work will have the meanings given to them in the Agreement.

 

Approach

[DESCRIBE METHODS/PROCESSES/TASK SUMMARY
of the Services – if a proposal was provided, this is most likely outlined in the proposal and can be copied here]

 

Deliverables

[DESCRIBE EXACTLY WHAT IT IS THAT ARQULE
IS RECEIVING AS A RESULT OF THE SERVICES]

 

Project Results

[DESCRIBE ITEMS RESULTING FROM THE
PERFORMANCE OF THE SCOPE OF WORK THAT WILL BE OWNED PURSUANT TO THE PROJECT RESULTS SECTION IN THE AGREEMENT]

 

Intellectual Property

Pursuant to section 6 of the Agreement,
the Parties intend that the following provisions control with respect to Parties’ respective rights to intellectual property.

[DESCRIBE IP RIGHTS AND OBLIGATIONS]

 

[optional] Obligations of ArQule

[DESCRIBE EXACTLY WHAT, IF ANYTHING,
ARQULE MUST PROVIDE SO THAT ARUP CAN SUCCESSFULLY PROVIDE SERVICES]

 

Project Assumptions

 

		1)	With respect to any intellectual
                                         property license reasonably necessary for ARUP to perform the Services contemplated hereunder,
                                         such license shall be readily available and will be timely procured at ArQule’s
                                         expense.

 

     

     

    

 

[optional] Specifications

 

Points of Contact

For ArQule:

ArQule

Address

Attention:

Tel:

Email:

 

For ARUP:

ARUP Laboratories, Inc.

500 Chipeta Way

Salt Lake City, UT 84108

Attention: Karen A. Heichman, PhD

Director, PharmaDx

Phone: (801) 584-5068

Email: karen.heichman@aruplab.com

 

Budget

[DESCRIBE ENTIRELY WHAT IT IS THAT
ARQULE IS AGREEING TO PAY FOR WITH RESPECT TO THE SERVICES – if a proposal was provided, this is most likely outlined in
the proposal and can be copied here]

 

Payment Schedule

 

[PICK ONE OF THE THREE LISTED BELOW]

Time & Materials Basis:
as invoiced by ARUP at the rates set forth below; provided, however, that ARUP will obtain ArQule’s prior written approval
before providing more than [_____ dollars ($__.__)] worth of Services.

 

Rates:

 

Fixed Fee Basis: Total fee of
[_____ dollars ($__.__)] payable in [_____ (__)] installments of [_____ dollars ($__.__)] each.

 

Milestone Fee Basis: Fees payable
in accordance with the table immediately below and the development schedule of this Scope of Work.

 

	Milestone	 	Fee (US$)
	 	 	 
	 	 	 
	 	 	 

 

     

     

    

 

Term

The term of this Scope of Work will begin
on ___________ and shall terminate on ____________.

 

	ArQule, Inc.	 	ARUP Laboratories,
    Inc.
	 	 	 
	Signed:	 	Signed:
	 	 	 
	Name:	 	Name:
	 	 	 
	Title:	 	Title:
	 	 	 
	Dated:	 	Dated:

 

     

     

    

 

EXHIBIT
1

 

Supplier
***

 

	‒	 
	‒	*** (the “Product”)
	 	***
	 	 
	 	***
	 	 
	 	This Product is designed for in vitro diagnostic use
    only. This Product is a ready-to-use reagent (i.e. "one vial solution").
	 	 
	 	Interpretation of the results must be made within the context
    of the patient ́s clinical history with respect to further clinical and pathologic data of the patient by a qualified
    pathologist.
	 	 
	 	The result should be considered in the clinical context (including
    therapeutical decision). Thus, this Product is not in relation to a clinical therapy, and, thus, it is not a companion diagnostic.
	 	 
	‒	Products will be delivered with minimum shelf life mentioned in the *** Supply Agreement.Exhibit 10.3

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

Scope
of Work #1

 

This Scope of Work (this “Scope of
Work” or “SOW”) is incorporated into the Master Services Agreement dated July 20, 2017 by and between
ArQule and ARUP (for the purposes of this Scope of Work, the “Agreement”). This Scope of Work describes Services
and Deliverables to be performed and provided by ARUP pursuant to the Agreement. In the event of any conflict between the Agreement
and any provision of this Scope of Work, the Agreement will control unless the Parties’ intent to alter the terms of the
Agreement is expressly set forth in such provision, and such alteration shall only apply to this Scope of Work and shall not be
construed as an amendment to the terms of the Agreement or to any other Scope of Work. All capitalized terms used and not expressly
defined in this Scope of Work will have the meanings given to them in the Agreement.

 

Overview 

The goal of this Scope of Work is to develop
and validate a FGFR2 FISH assay to be used as an IOU patient selection diagnostic for the ARQ 087 compound in connection with a
registrational Phase 3 trial in intrahepatic cholangiocarcinoma (the “Phase 3 Trial”) and to further validate
and seek FDA approval for such assay as a Companion Diagnostic under the FDA’s Humanitarian Device Exemption (HDE) for commercialization
in accordance with such regulations. The end point for the existing trial is overall response rate. The parties acknowledge that
ArQule may decide to pursue a trial endpoint of progression free survival. In such case, ArQule agrees to keep ARUP apprised of
its decision making, and the details of the new trial and protocol for the study will be shared with ARUP if and when made. For
purposes hereof, either trial shall be known as the Phase 3 Trial. Testing to support the Phase 3 Trial is outside the scope of
this SOW and will be included in a subsequent Scope of Work. For purposes of this Scope of Work #1, any reference herein to the
FGFR2 FISH assay shall mean the ARUP IUO or ARUP Companion Diagnostic, as applicable.

 

Approach

		1.	ARUP will conduct its existing design control program,
termed the “Product Development Program” or “PDP”, to develop and validate the FGFR2 FISH
assay in accordance with the FDA Quality System Regulations, 21 CFR part 820.

 

		2.	ARUP will prepare a modular application for the FGFR2 FISH
assay as a companion diagnostic for the ArQule compound ARQ 087 and will use Commercially Reasonable Efforts to obtain regulatory
approval for the FGFR2 FISH assay under the FDA’s Humanitarian Device Exemption (“HDE”) Program. In the
event that the FDA does not grant a Humanitarian Use Device (“HUD”) designation or permit the transfer of such
HUD designation to ARUP to enable ARUP to offer the companion diagnostic the Parties shall, at ArQule’s request, amend this
SOW to pursue a PMA for such companion diagnostic and ArQule will be responsible for the incremental costs and expenses related
to the additional work performed by ARUP in connection therewith and in connection with the preparation and filing of any required
regulatory applications, which costs and expenses will in all cases be reasonable and consistent with the billing practices and
procedures used by ARUP under this Agreement. ArQule and ARUP contemplate entering into the *** Supply Agreement with the Supplier
substantially contemporaneous with this SOW on terms mutually acceptable to ArQule, ARUP and the Supplier, pursuant to which the
Supplier will agree to provide support to ARUP as an *** and supply ARUP with certain quantities of the Supplier *** and ArQule
will agree to be responsible for all costs associated with supply of the Supplier *** to ARUP.

 

    	 	A-1	 

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

		3.	ARUP will develop, validate, and maintain the HDE assay
in accordance with the FDA Quality System Regulations for Medical Devices and the HDE requirements.

 

		4.	ARUP will submit a request for, and use commercially reasonable
efforts to obtain, HUD designation from the FDA for the assay being verified and validated by ARUP under the PDP design control
program. Once the HUD designation has been granted to ARUP, ARUP will remain solely responsible for all interactions with the
FDA’s Center for Devices and Radiological Health (CDRH) regarding the assay, including but not limited to interactions such
as scheduling all meetings with the CDRH, preparing and submitting meeting minutes, validation plans, the HDE application and
amendments, and annual reports. ArQule will not contact CDRH about the test without providing ARUP with prior written notification
and the opportunity to participate. Notwithstanding the foregoing ARUP may request that ArQule participate in any or all interactions
with the FDA regarding the FGFR2 FISH assay.

 

		5.	ARUP will notify ArQule in advance of all material meetings
relating to the test, whether in person or by telephone or videoconference, and all other material communications, scheduled with
regulatory agencies. ArQule shall be entitled to attend and participate in such meetings with regulatory agencies, in person or
by means of telecommunication. ArQule’s participation may, for example, include providing regulatory authorities with the
pharmaceutical development perspective, including the therapeutic and diagnostic issues related to drug clinical trials and patient
specimens and clinical report forms collected in support of the application submission, as well as information on the relationship
between the use of the companion diagnostic and its relevance to ARQ 087 and the treatment of patients; provided, however, that
the Parties shall jointly agree on this support prior to communication to or with regulatory authorities. Prior to ARUP’s
submission of any filing to a regulatory authority, the Parties shall jointly review and approve such a filing. ARUP will create
meeting minutes from FDA interactions and provide such to ArQule along with any FDA acknowledgements (e.g. receipt of modules).

 

		6.	Upon FDA approval of the FGFR2 FISH assay, ARUP will perform
the assay in accordance with FDA regulations and make such assay publicly available for as long as requested by ArQule, provided
that ArQule continues to make the annual Maintenance Payments under the Agreement. In the event that ARUP is no longer capable
of performing the FDA-approved FGFR2 FISH assay for some unforeseen reason not within ARUP’s reasonable control such as
the termination of the *** Supply Agreement with the Supplier for supply of the *** and other than as a result of the breach of
this Agreement by ARUP, ARUP will, at ArQule’s request and expense, use commercially reasonable efforts to enable another
United States laboratory to offer the assay, or acceptable substitute companion diagnostic for the ArQule compound ARQ 087, including
by using commercially reasonable efforts to minimize any risk of interruption of the availability of the assay. Following FDA
approval of the FGFR2 FISH assay, ARUP will cooperate with ArQule, at ArQule’s request and expense, and pursuant to terms
and conditions set forth in an additional SOW mutually acceptable to the Parties, to enable other laboratories outside the United
States to offer the assay, or acceptable substitute companion diagnostic for the ArQule compound ARQ 087.

 

    	 	A-2	 

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

		7.	ARUP shall provide information regarding preanalytical
aspects of the FGFR2 FISH assay and pertaining to general laboratory practices, such as specimen collection, transport, storage,
preparation and handling for use with the assay. ArQule shall have the right to disseminate broadly to laboratories outside the
United States such information as is necessary for such laboratories to practice these general preanalytical methods in a manner
consistent with the assay performed in the Phase 3 Clinical Trial. For the avoidance of doubt, the PDP, including all related
processes and documents used in the generation of the HDE assay, will remain the sole property of ARUP and may not be sub-licensed
by any other laboratories for any use without ARUP’s express written consent.

 

		8.	ARUP will perform Services in furtherance of the goal of
this SOW substantially as set forth in the following table:

 

	Services	 	Description
	Project Initiation	 	
        Project initiation

        ·     Contracting

        ·     On-site
        quality audit of ARUP (2 days and up to 3 auditors)

        ·     Project
        charter

        ·     Project
        planning process

        ·     Establishment
        of design team and weekly team meetings

        ·     Commencement
        of design control activities, including initial design risk assessment activities

        ·     Establishment
        of design requirements including, but not limited to: product description, assay functional requirements, assay performance specifications,
        hardware/software requirements, manufacturing/QC specifications, regulatory requirements, draft Verification Master Plan, draft
        Validation Master Plan

        ·     Initiation
        of purchasing controls for critical components

        ·     In-sourcing
        of materials

         

	Humanitarian Use Device (HUD) Request	 	
        Preparation of HUD request

        ·     Collection
        of literature to support rare disease (<8,000 in US/year)

        ·     Preparation
        of HUD request and submission to FDA

        

 

    	 	A-3	 

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

	Services	 	Description
	Investigational Device Exemption (IDE)	 	
        Investigational Device Exemption activities

        Assumption: FGFR2 FISH assay will be significant risk
        (SR)

        ·     Preparation
        of request for pre-IDE meeting to discuss IDE development and validation plan

        ·     Submission
        of pre-IDE meeting request to FDA

        ·     Briefing
        book preparation

        ·    FDA
        pre-IDE meeting and slide preparation

        ·     Preparation
        of slide deck, dialog with FDA

        ·     Fulfillment
        of IDE requirements including labeling, investigational plan, subject selection criteria, informed consent

        ·     Review
        and revision of IDE application

        ·     Submission
        of IDE application

        ·     Preparation
        of IRB application

        ·     Payment
of IRB fees

	 	 	 
	ARUP IUO Development & Validation	 	
        ARUP IUO Development and Validation 

        ·     Feasibility
        studies of conducting assay using ARUP standard FISH method

        ·     Establishment
        of assay reference range, sensitivity, specificity

        ·     Verification
        of ARUP IUO performance (concordance, reproducibility/precision)

        ·     Transfer
        of assay to clinical lab including training of operators

        ·     Preparation
        of quality plan

        ·     Preparation
        of experimental coversheets

        ·     Preparation
        of results, summaries

        ·     Preparation
        of protocol history table with itemization of protocol changes

        ·     Quality
        audits

        ·     Medical
        director approvals

        ·     Executive
        approvals

 

    	 	A-4	 

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

	Services	 	Description
	Design Control	 	
        Implementation of Design Control (Phase 1-3)

        ·     Design
        control documentation including, but not limited to, project plan, project schedule, component list, design history file, checklists,
        summaries

        ·     Supplier
        assessment and drafting of component specifications under purchasing controls

        ·     Preliminary
        hazard analysis and failure mode and effects analysis (FMEA); multiple and iterative

        ·     Finalization
        and approval of assay SOP and forms

        ·     Development
        of process documents (batch records)

        ·     End
        of phase design reviews

        ·     Preparation
        of MasterControl organizer

        ·     Development
        of Device Master Record

        ·     Design
        History File development and audit

        ·     Laboratory
        notebook, correspondence, memo and meeting minutes maintenance

	 	 	 
	HDE Application Preparation	 	
        HDE application preparation

        ·    Modular
        submission: quality/manufacturing, analytical, clinical, software

        ·    Required
        forms and sections including coversheet, indications for use, summary, description of disease and assay, results, summary of safety
        and probable benefit, product description

        ·    Development
        and iterative revision of labeling documents (test request form, physician instructions, product datasheet, website)

        ·    Literature
        review and reference collection

        ·    Development
        of FDA interaction history

        ·    Collection
        of all referenced documents (current versions; estimated 100-150)

        ·    Electronic
        and paper copies of modules

        ·    Document
        archiving

 

    	 	A-5	 

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

	Services	 	Description
	HDE Approval and Post-Approval Activities	 	
        HDE approval and post-approval activities
        

        ·     IRB
        application and approval

        ·     Build
        of test in ARUP’s laboratory information system (LIS) 

        ·     Validation
        of test build 

        ·     Addition
        of test to ARUP’s laboratory test directory 

        ·     Development
        of test-specific website 

        ·     Registration
        of test with FDA 

        ·     Physician
        IRB enrollment instructions 

        ·     Training
        of Client Services 

        o     Test
        ordering information for ARUP non-clients

        o     Other
        test-specific topics included but not limited to IRB enrollment requirements for ordering physicians (HDE requirement), intended
        use, specimen requirements

        ·     Maintenance
        of test under QSR (21 CFR Part 820) and all FDA conditions of approval

        ·     Complaint
        handling

        ·     Medical
        device reporting

         

	HDE Application Amendments	 	
        Estimate of two (2) amendments

        *Note – this does not include
        additional experimentation if required by FDA.

	 	 	 
	Companion Diagnostic (CDx) Development & Validation	 	
        Additional assay development & validation activities required
        for CDx to include but not limited (final determined in conjunction with Sponsor and FDA):

        ·    To
        conduct any required bridging studies 

        ·    Sensitivity
        

        ·    Specificity
        

        ·    Interference
        

        ·    Reproducibility
        (including Intra-Run, Inter-Run) 

        ·    Guard-banding
        

        ·    Specimen
        stability 

        ·    Reagent
        stability 

        ·    Accuracy
        

         

 

    	 	A-6	 

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

	Services	 	Description
	Design Control	 	
        Design Control (Phase 3-5)

        Implementation of design control under ARUP's PDP Program portion
        of the Quality Management System including:

         

        ·     Phase
        3 – Design Verification (2nd part) 

        ·     Phase
        4 – Design Transfer 

        ·     Phase
        5 – Design Validation

         

        

        Regulatory
oversight throughout the assay lifecycle with regards to quality audits, document controls, design controls, design reviews, purchasing
controls, software validation, risk management, change controls, process controls and CAPA to maintain compliance with QSR (21
CFR §820.30).

 

Meeting and Reporting Schedule

		1.	ARUP will host teleconferences with ArQule not less than
*** per calendar month, with meeting minutes prepared and shared with ArQule.

 

		2.	ARUP will provide written *** reports of the progress of
its activities in reasonable detail, including (i) a description of activities for the past quarter, any key accomplishments,
milestones, deviations, or delays, including, to the extent applicable, mitigation plans and/or suggestions for further discussion
by the Parties respective Point of Contact; and (ii) a summary statement regarding the tracking of the project against the Activities
and Milestones described below.

 

		3.	ARUP will host *** meetings or will agree to otherwise
meet with ArQule at least ***.

 

Obligations of ArQule

		1.	ArQule will make payments to ARUP as outlined in Exhibit
B and as directed in the Agreement.

 

		2.	ArQule will make annual payments to ARUP following the
one year anniversary of FDA approval of the assay for as long as ArQule requires ARUP to maintain the FDA-approved assay on its
test menu (“Maintenance Payments”).

 

		3.	ArQule will reimburse ARUP for necessary travel expenses
related to work performed under this Statement of Work. Any travel expenses for which ARUP seeks reimbursement under this Statement
of Work must be pre-approved by ArQule in writing.

 

		4.	ArQule will remain solely responsible for all interactions
with the FDA’s Center for Drug Evaluation and Research (CDER). Upon request, ARUP will assist in interactions with the FDA
regarding ARQ 087 and the Phase 3 Trial.

 

    	 	A-7	 

     

    

 

Confidential
                                         Materials omitted and filed separately with the Securities and Exchange Commission.

                                         ***Triple asterisks denote omissions.

 

Intellectual Property

 

		1.	The Parties hereby agree that Article 6 of the Agreement
shall control the Parties’ ownership of, and respective rights to, Background Know-How, Background Patents and Inventions
under this Scope or Work The following provisions are intended to supplement, and not amend, Article 6 of the Agreement:

 

For purposes of clarification, ARUP
Background Know-How includes but is not limited to the following:

 

		a.	PDP policy, processes, procedures, forms, strategies, best
practices and know-how.

 

		b.	Other laboratory, diagnostic or business practices inherent
to a national reference laboratory or specific to ARUP.

 

		2.	Academic and Research Use FGFR2 FISH Data

Publications or presentations pertaining
to the FGFR2 FISH data will be handled on a case-by-case basis. Each party has a right to review any proposed disclosures of data
generated under this SOW pertaining to the FGFR2 FISH assay, including but not limited to publications, presentations or press
releases for the purpose of protecting against disclosure of confidential information that would be prejudicial to the rights of
the reviewing party. The disclosing party must provide the other party a minimum of *** days to review the proposed disclosure
and to provide input, provided that if no feedback is provided within *** days, the proposed publication shall be deemed approved.

 

Points of Contact: 

 

For ArQule:

ArQule, Inc.

One Wall Street, Burlington, MA 01803

Attention: Ron Savage

Title: Senior Director, Preclinical Development

Tel: 781-994-0300

Email: rsavage@arqule.com

 

With a copy to Peter S. Lawrence

Email: plawrence@arqule.com

 

For ARUP:

ARUP Laboratories, Inc.

500 Chipeta Way

Salt Lake City, UT 84108

Attention: Karen A. Heichman, PhD

Director, PharmaDx

Phone: (801) 584-5068

Email: karen.heichman@aruplab.com

 

    	 	A-8	 

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

Exhibit B - Activities, Budget and Payment
Schedule

 

Milestone Fee Basis: Fees payable in accordance
with the table immediately below. All milestones to be invoiced upon ArQule’s acceptance of Milestone Achievement. All ARUP
invoiced milestones are non-refundable. Timelines in the table below assume a July 1, 2017 start date of the Agreement and are
meant to be estimates.

 

	Milestone Payment Schedule	 	 	 
	Milestone	 	 	 	Cost	 
	1 
7/1/2017	 	Project Initiation* 
 Evidence of milestone achievement – Execution of Master Services Agreement including SOW #1
	 	$	***	 
	 	 	 	 	 	 	 
	2 
9/1/2017	 	Humanitarian Use Device Exemption (HUD)*
 Evidence of milestone achievement – Notification from FDA of receipt of HUD request
	 	$	***	 
	 	 	 	 	 	 	 
	3a 
8/1/2017	 	Investigational Device Exemption (IDE)*
 Evidence of milestone achievement – Submission of request for pre-IDE meeting to CDRH and acknowledgement of delivery
	 	$	***	 
	 	 	 	 	 	 	 
	3b 
4/1/2018	 	IDE application
 Evidence of milestone achievement – Notification from CDRH of successful IDE application
	 	$	***	 
	 	 	 	 	 	 	 
	Subtotal of Initiation Activities	 	$	***	 
	 	 	 	 	 
	4a 
8/1/2017	 	ARUP IUO Analytical Development and Validation*
 First 50% of activity
 Evidence of milestone achievement – ArQule’s review and acceptance of development and validation plan. 
	 	$	***	 
	 	 	 	 	 	 	 
	4b 
2/1/2018 
	 	ARUP IUO Analytical Development and Validation*
 Second 50% of activity
 Evidence of milestone achievement – ArQule’s review and acceptance of ARUP IUO validation report.
	 	$	***	 
	 	 	 	 	 	 	 
	5a 
7/1/2017	 	Design Control for ARUP IUO(Phases 1-3)*
 First 50% of activity
 Evidence of milestone achievement – ArQule’s review and acceptance of design control plans and Project Charter
	 	$	***	 

 

     

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

	5b 
2/1/2018	 	Design Control for ARUP IUO (Phases 1-3)*
 Second 50% of activity
 Evidence of milestone achievement – completion of ARUP IUO validation
	 	$	***	 
	 	 	 	 	 	 	 
	Subtotal of  ARUP IUO Verification and Design Controls	 	$	***	 
	 	 	 	 	 
	6a 
6/1/2018	 	HDE Application Preparation*
 First 50% of activity
 Payable upon commencement of application preparation.
	 	$	***	 
	 	 	 	 	 	 	 
	6b 
TBD	 	HDE Application Preparation*
 Second 50% of activity
 Evidence of milestone achievement – evidence of receipt by CDRH
	 	$	***	 
	 	 	 	 	 	 	 
	6c 
TBD	 	HDE Application Amendments*
 (if
                                         required)
 Each
                                         amendment is $*** with a **% project management fee (estimated that two (2) amendments
                                         may be needed)
 Evidence of milestone achievement – Acknowledgement of receipt by CDRH
	 	$	***  **	 
	 	 	 	 	 	 	 
	Subtotal of HDE Application Costs	 	$	***	 
	 	 	 	 	 
	7a 
2/1/2018	 	Companion Diagnostic (CDx) Development and Validation*
 First 50% of activity
 Evidence of milestone achievement – ArQule’s review and acceptance of validation plan
	 	$	***	 
	 	 	 	 	 	 	 
	7b 
2/1/2019	 	Companion Diagnostic (CDx) Development and Validation*
 Second 50% of activity
 Evidence of milestone achievement – ArQule’s review and acceptance of validation report
	 	$	***	 

 

     

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

	8a 
2/1/2018	 	Design Control (Phases 3-5)*
 First 50% of activity
 Evidence of milestone achievement – ArQule’s review and acceptance of validation plan
	 	$	***	 
	 	 	 	 	 	 	 
	8b 
2/1/2019	 	Design Control (Phases 3-5)*
 Second 50% of activity
 Evidence of milestone achievement – completion of Phase 5 Design Validation summary 
	 	$	***	 
	 	 	 	 	 	 	 
	9 
3/1/2019	 	Development of the final CDx test procedure (SOP)*	 	$	***	 
	 	 	 	 	 	 	 
	10 
3/1/2019	 	Submission Plan Preparation*	 	$	***	 
	 	 	 	 	 	 	 
	Subtotal of CDx Validation and Design Controls	 	$	***	 
	 	 	 	 	 
	11 
TBD	 	Registration of the test with FDA*
 Evidence of milestone achievement – Acknowledgement of registration receipt by the FDA
	 	$	***	 
	 	 	 	 	 	 	 
	12 
TBD	 	Preparation of IRB (post-approval)*
 Evidence of milestone achievement – Acknowledgement of submission by the University of Utah IRB
	 	$	***	 
	 	 	 	 	 	 	 
	13 
TBD	 	Development and Maintenance of Website for Test*
 Evidence of milestone achievement – Release of Test on ARUP’s Test Directory
	 	$	***	 
	 	 	 	 	 	 	 
	Total Milestone Costs (not including optional costs)	 	$	***	 

 

*Costs include a ***% project management fee

**Optional costs not included in subtotal

 

     

     

    

 

Confidential
                                         Materials omitted and filed separately with the Securities and Exchange Commission.

                                         ***Triple asterisks denote omissions.

 

Additional Costs

Additional costs are described in the table
below and are to be invoiced upon ArQule’s acceptance of evidence of achievement.

 

	Additional Costs
	Type	 	Details	 	 	Cost
	Travel	 	
        Travel to meetings including

        ·     Pre-submission
        meetings

        ·     Travel
        to ArQule up to *** yearly

        ·     Travel
        must be in accordance with ArQule’s Travel Policy

        Evidence of achievement – Receipts
attached to invoice 
	 	 	TBD
	 	 	 	 	 	 
	
        License agreement

        (if required)
	 	
        Third-party license agreement if required to practice the FGFR2
        FISH assay

        ·     Upfront
        license fee

        ·     Royalties

        ·     Other
fees 
	 	 	TBD
	 	 	 	 	 	 
	
        Assay Annual Maintenance Fee

         
	 	
        Annual assay maintenance

        ·     Training
        of personnel

        ·     Troubleshooting

        ·     Instrument
        service contract

        ·     Instrument
        preventive maintenance

        ·     Proficiency
        testing (CAP requirement)

        ·     Annual
        device report to FDA

        ·     Reagent
        procurement, qualification and performance monitoring of critical component suppliers

        Evidence
of achievement – Acknowledgement of annual device report submission to FDA
	 	$	***

 

Term

The term of this Scope of Work will begin on
July 20, 2017 and shall terminate on completion of all activities described in this Scope of Work, unless earlier terminated by
the Parties in accordance with the Agreement.

 

     

     

    

 

Confidential Materials omitted and filed
separately with the Securities and Exchange Commission.

***Triple asterisks denote omissions.

 

	ArQule, Inc.	 	ARUP Laboratories, Inc.
	 	 	 
	Signed:	/s/ Peter S. Lawrence	 	Signed:	 /s/ Sherrie L. Perkins 
	 	 	 	 	 
	Name:	Peter S. Lawrence	 	Name:	 Sherrie L. Perkins MD PhD 
	 	 	 	 	 
	Title:	President and Chief Operating Officer	 	Title:	 SVP Research 
	 	 	 	 	 
	Dated:	July 20, 2017	 	Dated:	July 20, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]